NCT04009668View on ClinicalTrials.gov

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 2, 2019

Primary Completion Date

September 5, 2023

Study Completion Date

October 3, 2023

Conditions
FSGSMCDFocal Segmental GlomerulosclerosisMinimal Change Disease
Interventions
DRUG

adalimumab

Adalimumab will be dosed based on weight

Trial Locations (4)

10016

New York University, New York

28207

Levine Children's Hospital/Atrium Health, Charlotte

44195

Cleveland Clinic Foundation, Cleveland

48109

The University of Michigan, Ann Arbor

All Listed Sponsors
lead

University of Michigan

OTHER

NCT04009668 - Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease | Biotech Hunter | Biotech Hunter